Quantcast
Last updated on April 20, 2014 at 17:20 EDT

Latest Hematopathology Stories

2014-04-14 12:33:36

MST-188 decreased a marker of inflammation and red blood cell aggregation (50% reduction relative to control) SAN DIEGO, April 14, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in an ex vivo study conducted at Loyola University Medical Center, MST-188 reduced the mean erythrocyte sedimentation rate (ESR) by 50% relative to control in blood collected from individuals with sickle cell disease. ESR, a common laboratory test and measure of inflammation,...

2014-04-04 23:41:03

The campaign encourages donors and those affected by Sickle Cell to recruit six friends in their networks to help children afflicted with sickle cell. The Foundation urges interested parties to share information provided about sickle cell with six other people and to consider the impact they can have on the lives of chronically-ill children. Atlanta, GA (PRWEB) April 03, 2014 The Sickle Cell Foundation of Georgia, Inc. inspired by successful crowd funding campaigns in social media, has...

2014-04-01 13:25:25

Child and adolescent hematologists at Boston Medical Center (BMC) have developed a tool to gauge how ready young adults with sickle cell disease are for a transition into adult care. In a new article for the Journal of Pediatric Hematology/Oncology, Amy Sobota, MD, MPH, and her collaborators have shown that a questionnaire geared to the needs of young adults with sickle cell disease can pinpoint areas of need before the patient goes into an adult clinic. BMC's sickle cell disease...

2014-03-27 12:30:04

TUCSON, Ariz., March 27, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group has made an educational grant to support the World Health Organization (WHO) Clinical Advisory Meeting being held March 31 through April 1, 2014 in Chicago. The meeting's purpose is to update the existing WHO monograph on Tumours of the Haematopoietic and Lymphoid Tissues published in 2008. The meeting will be attended by up to 100 global experts in the field of...

2014-03-19 08:28:51

TORRANCE, Calif., March 19, 2014 /PRNewswire/ -- Emmaus Life Sciences, Inc. (the "Company," or "Emmaus"), a biopharmaceutical company dedicated primarily to the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that preliminary top-line results of its Phase 3 clinical trial evaluating the safety and efficacy of its treatment for sickle cell anemia and sickle beta-0 thalassemia met both the primary and...

2014-03-03 04:22:38

- This Trial, Together with PERSIST-1, to Support Registration in the U.S. and Europe - SEATTLE, March 3, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300...

2014-03-02 23:01:36

A Canadian lymphoma expert says the ability to understand the influence of genes in disease could be a vital step forward in the treatment of Non-Hodgkin’s Lymphoma. Raleigh, NC (PRWEB) March 02, 2014 According to a report from the Non-Hodgkin’s Lymphoma Center, the head of British Columbia’s Centre for Lymphoid Cancers says knowledge of genetic mutations in cancers like Non-Hodgkin’s Lymphoma is “perhaps as powerful and revealing as the introduction of the microscope in the...

2014-01-24 11:33:02

Patients with sickle cell trait require more anemia drugs The presence of sickle cell trait among African Americans may help explain why those on dialysis require higher doses of an anemia medication than patients of other ethnicities, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN). Additional studies are needed to determine the long-term health consequences of this increased dosing. Sickle cell trait represents the...

2014-01-07 08:30:43

TORRANCE, Calif., Jan. 7, 2014 /PRNewswire/ -- Emmaus Medical, Inc. (the "Company," or "Emmaus"), a biopharmaceutical company engaged in the discovery, development and commercialization of innovative and cost-effective treatments and therapies primarily for rare and orphan diseases, today announced it has completed all patient visits for its Phase 3 clinical trial for the treatment of sickle cell disease. Emmaus expects top-line data from the Phase 3 clinical trial to be available in...

2014-01-07 08:30:05

FT. MYERS, Fla., Jan. 7, 2014 /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has validated and launched a new test for the detection of mutations in the calreticulin (CALR) gene. The CALR gene is a novel biomarker that was reported to be specific for myeloproliferative neoplasms (MPN) for the first time at the annual meeting of the American Society of Hematology (ASH) last month. Since then, findings...